Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Communications and UpdatesFull Access

Correction

Published Online:1 May 2014https://doi.org/10.1176/appi.ajp.2014.1715correction

After the April issue went to press, a small error and omission was noted in the article “Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism” by Henry R. Kranzler, M.D., et al. (Am J Psychiatry 2014; 171:Original article: 445–452). In the 4th paragraph of the introduction, the sentence should read “Topiramate's effects on glutamate receptors are most potent and selective for those containing the GluK1 and GluK2 (formerly referred to as GluR5 and GluR6) subunits (encoded by GRIK1 and GRIK2, respectively).” This information was updated for the online edition of the article and for the accompanying PDF.